

## **WHO-PQ RECOMMENDED PATIENT INFORMATION LEAFLET**

*This patient information leaflet focuses on uses of the medicine covered by WHO's Prequalification Team - Medicines. The recommendations for use are based on WHO guidelines and on information from stringent regulatory authorities.\**

*The medicine may be authorised for additional or different uses by national medicines regulatory authorities.*

---

\* [https://extranet.who.int/pqweb/sites/default/files/documents/75%20SRA%20clarification\\_Feb2017\\_newtempl.pdf](https://extranet.who.int/pqweb/sites/default/files/documents/75%20SRA%20clarification_Feb2017_newtempl.pdf)

## Information for the patient

[TB172 trade name]<sup>†</sup>  
Pyrazinamide

*The warnings and instructions in this leaflet are intended for the person taking the medicine.  
If you are a parent or carer responsible for giving the medicine to someone else such as a child,  
you will need to apply the instructions accordingly.*

### **Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have questions about the medicine, ask your health care provider.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness seem to be the same as yours.
- If you are concerned about any side effects, talk to your health care provider. This includes unwanted effects not listed in this leaflet. See section 4.

### **What is in this leaflet**

1. What [TB172 trade name] is and what it is used for
2. What you need to know before you take [TB172 trade name]
3. How to take [TB172 trade name]
4. Possible side effects
5. How to store [TB172 trade name]
6. Contents of the pack and other information

#### **1. What [TB172 trade name] is and what it is used for**

[TB172 trade name] is a medicine used to treat tuberculosis (TB), an infection caused by bacteria called *Mycobacterium tuberculosis*. It is always given together with other medicines to treat tuberculosis. Your health care provider has chosen the combination that is right for your condition.

[TB172 trade name] contains the active substance pyrazinamide and belongs to a group of antibiotics called antimycobacterials.

#### **2. What you need to know before you take [TB172 trade name]**

##### **Do not take [TB172 trade name] if you**

- are allergic (hypersensitive) to pyrazinamide or any of the other ingredients in [TB172 trade name] (see section 6);
- have severe liver disease;
- have acute gout;
- have porphyria.

##### **Talk to your health care provider before taking [TB172 trade name] if you**

- have liver or kidney problems;
- have diabetes;
- have a history of gout;
- are allergic to ethionamide, isoniazid or niacin (nicotinic acid).

In case of impaired kidney function, your health care provider may decide to adjust the dose.

---

<sup>†</sup> Trade names are not prequalified by WHO. This is the national medicines regulatory agency's responsibility.

Your health care provider will check your blood for liver function and metabolic changes before starting therapy, and at regular intervals during treatment with [TB172 trade name].

If you are allergic to ethionamide, isoniazid or niacin (nicotinic acid), you should inform your health care provider, because you may also be allergic to [TB172 trade name].

### **Taking other medicines**

Please tell your health care provider if you are taking, or have recently taken, any other medicines, including medicines obtained without a prescription. These may affect the action of [TB172 trade name], or [TB172 trade name] may affect their action.

In particular, tell your health care provider if you are taking:

- probenecid, sulfapyridine or allopurinol (medicines for treating gout);
- medicines that may affect your liver function such as rifampicin, isoniazid and ethionamide;
- oestrogen medicines for contraception since [TB172 trade name] may reduce their contraceptive effects.

Do not take [TB172 trade name] together with ofloxacin or levofloxacin, unless your health care provider tells you to do so.

Alcohol may increase the risk of liver disease. Avoid alcoholic drinks while using this medication.

Pyrazinamide may cause live bacterial vaccines (such as typhoid vaccine) to not work well. Tell your health care provider that you are using pyrazinamide before having any immunizations/vaccinations.

### **Taking [TB172 trade name] with food and drink**

[TB172 trade name] is not affected by food and drink and may be taken with meals or in between meals.

### **Pregnancy and breastfeeding**

If you become pregnant, or are planning to become pregnant, you must contact your health care provider to discuss the potential benefits and risks of your tuberculosis therapy to you and your child.

Pyrazinamide is excreted into breast milk. However, no negative effects have been reported in breastfed infants, whose mothers were receiving pyrazinamide.

[TB172 trade name] can be used during breastfeeding.

### **Driving and using machines**

[TB172 trade name] is unlikely to affect the ability to drive and use machines.

## **3. How to take [TB172 trade name]**

Always take [TB172 trade name] exactly as your health care provider has told you. You should check with your health care provider if you are not sure.

You can take [TB172 trade name] with meals or in between meals. Try to take the tablet(s) at approximately the same time each day.

The dose, the interval between doses of [TB172 trade name] and the length of treatment is decided by your health care provider based on your body weight, your condition and the other medicines you are taking for treating tuberculosis.

If you have kidney disease your health care provider may tell you to take [TB172 trade name] three times per week instead of daily.

In the case of tuberculous meningitis your healthcare provider may prescribe a different dosing regimen.

[TB172 trade name] is always given in combination with other antituberculosis agents; please make sure to follow the instructions of your health care provider.

*Recommended number of [TB172 trade name] tablets*

<b>Weight</b>	<b>Daily dose</b>
3 – <5 kg	0.2* tablet
5 – <10 kg	0.5*tablet
10 – <16 kg	1 tablet
16 – <24 kg	1.5* tablets
24 – <36 kg	2 tablets
36 – <46 kg	3 tablets
46 – <70 kg	3 tablets
>70 kg	4 tablets

\* When needed, the tablets can be broken in half along the scoreline, but further breaking into smaller doses is not possible. In these cases, an extemporaneous mixture may be prepared (see below), but if available other formulations such as dispersible tablets containing lower amounts of pyrazinamide should preferably be used.

If needed, an extemporaneous mixture may be prepared by mixing the tablet(s) of [TB172 trade name] with drinking water and the following volumes of extemporaneous solution should then be taken, according to the patient's weight:

<b>Child's weight</b>	<b>Number of tablets to be mixed with water</b>	<b>Volume of water to be used</b>	<b>Volume (dose) of extemporaneous solution to be given</b>
3 – <5 kg	1	10 mL of water	2 mL daily
5 – <10 kg	1	10 mL of water	5 mL daily
10 – <16 kg	1	10 mL of water	10 mL daily
16 – < 24 kg	2	20 mL of water	15 mL daily
24 – <36 kg	2	20 mL of water	20 mL daily
36 – <46 kg	3	30 mL of water	30 mL daily

For preparing the liquid mixture you need:

- One small bowl
- drinking water
- a teaspoon and
- an oral syringe.

The following steps should be applied:

1. Measure out the required amount of drinking water using the syringe (see dose table) and put it into the bowl.
2. Put the required number of [TB172 trade name] tablets (see dose table) into the bowl with the water.
3. Stir until dispersed.
4. Use the syringe to draw up the correct amount of liquid mixture from the bowl as instructed by your health care provider or look up the volume to be given in the table above. Make sure there are no bubbles in the mixture when you measure the amount drawn up.
5. Give the whole contents of medicine mixture in the syringe to the child.
6. You may give the child a little milk or liquid after giving the medicine, this will help with removing bitter aftertaste.
7. Throw away any remaining liquid left in the bowl.

Repeat these steps every time you need to give the medicine.

If you have any further questions on the use of this medicine, ask your health care provider.

**If you take more [TB172 trade name] than you should**

If you accidentally take more tablets than you should, tell a health care provider or get medical advice straight away. Take the medicine pack with you. This is so the health care provider knows what you have taken. If you

accidentally take too much medicine, you may result in increases in blood levels of uric acid and may cause liver damage.

#### **If you forget to give [TB172 trade name]**

If you forget to take a dose, take the missed dose as soon as you remember on the same day. If you do not remember on the same day, take the normal dose on the next day. Do not take a double dose to make up for forgotten dose. If you are unsure about what to do, ask your health care provider.

When you have to take [TB172 trade name] two or three times per week: In case you miss or forget to take a dose, then take the missed dose as soon as possible, unless the next regular dose is scheduled within 12 hours. If you vomit within 1 hour of taking [TB172 trade name], then you should take an extra dose. If vomiting occurs more than an hour after taking the dose, then you do not need to take an extra dose and can take the next dose as usual when it is due.

#### **If you stop taking [TB172 trade name]**

It is important that you complete the course of treatment even if you begin to feel better. If you stop taking [TB172 trade name] too soon, your infection may not be completely cured and the infection may return or your condition may get worse. The bacteria causing the infection may become resistant to [TB172 trade name].

#### **4. Possible side effects**

Like all medicines, [TB172 trade name] can cause side effects, although not everybody gets them. When treating tuberculosis, it is not always possible to differentiate between unwanted effects caused by [TB172 trade name] or those caused by any other medicines you may be taking at the same time.

For this reason, it is important that you inform your health care provider of any change in your health.

If you notice any of the following symptoms or side effects, **tell your health care provider immediately**:

- Nausea and vomiting
- Itching or yellowing of the skin
- joint pain (without signs of joint inflammation)
- Constipation or diarrhoea
- Muscle pain, tingling, numbness, weakness or paralysis
- Mental changes, such as anxiety, confusion, hallucinations, disorientation or paranoia.

#### **Other side effects:**

Tell your healthcare provider if you get any of the following side effects, especially if they get serious, or if you notice any other unexpected or unusual symptoms not listed in this leaflet.

#### **Very common** [ may affect more than 1 in 10]:

- increased liver enzymes
- high levels of uric acid in the blood
- flushing

#### **Common** side effects [may affect up to 1 in 10 people]:

- nausea, vomiting

#### **Uncommon** side effects [may affect up to 1 in 100 people]:

- jaundice (yellowing of the skin and eye white)

#### **Rare** side effects [may affect up to 1 in 1,000 people]:

- liver failure
- pellagra (disease presenting with diarrhoea, skin inflammation and impaired brain function [dementia], caused by a lack of niacin, a certain vitamin), aggravated porphyria (disorder of certain enzymes in the synthesis pathway of the red blood pigment)
- rash, sensitivity to (sun-)light, hives

The following side effects have also been reported, but it is unknown how often they may occur:

- headache, dizziness, nervousness, difficulty sleeping

- abdominal cramps, loss of appetite
- inflammation of the kidney (interstitial nephritis)
- general aches and pains, fever, weight loss, allergic reactions
- low red blood cell count, low white blood cell count. If the number of red blood cells is reduced you may have symptoms of tiredness or breathlessness and a reduction in your white blood cell count can make you more prone to infections.
- decrease of platelets (blood cells important for blood clotting). If you have a low platelet count you may notice that you bruise more easily.
- gouty arthritis
- high blood pressure.

### **Reporting of side effects**

If you get any side effects, talk to your health care provider. This includes unwanted effects not listed in this leaflet. If available, you can also report side effects directly through the national reporting system. By reporting side effects, you can help improve understanding about the safety of this medicine.

### **5. How to store [TB172 trade name]**

Keep this medicine out of the sight and reach of children.

Do not store above 30°C.

Do not use this medicine after the expiry date stated on the bottle, carton or blister, after “EXP”. The expiry date refers to the last day of that month.

Do not use this medicine if you notice visible signs of deterioration or that it is different from the description below (e.g., swollen tablets).

Do not throw away any medicines in wastewater or household waste. Ask your health care provider how to throw away medicines you no longer use. These measures will help protect the environment.

### **6. Contents of the pack and other information**

#### **What [TB172 trade name] contains**

- The active ingredient is pyrazinamide 500 mg.
- The other ingredients of [TB172 trade name] are colloidal anhydrous silica, hydrogenated castor oil, lactose monohydrate, maize starch, pregelatinised starch and purified talc.

#### **What [TB172 trade name] looks like and contents of the pack**

[TB172 trade name] are 12.7 mm white, flat, circular bevel-edged uncoated tablets with a break line on one surface and plain on the reverse. The tablets are about 5 mm thick.

The tablet can be divided into equal halves.

[TB172 trade name] is available as:

- 1,000 tablets in a sealed polythene bag, inside an HDPE container with silica gel and aluminium tagger seal.
- Carton pack (100 tablets) of 10 blister strips each of 10 tablets or (90 tablets) of 9 blister strips each of 10 tablets: primary packaging is a blister of aluminium foil and PVC/PVDC foil.
- Carton pack (672 tablets) of 24 blister strips each of 28 tablets: primary packaging is a blister of aluminium foil and PVC/PVDC foil.

**Supplier and Manufacturer**

***Supplier***

Micro Labs Limited  
# 31, Race Course Road  
Bangalore 560 001  
Karnataka, India  
Tel. No.: +91-80-22370451-54  
Fax No.: +91-80-22370463  
E-mail: [info@microlabs.in](mailto:info@microlabs.in)

***Manufacturer***

Micro Labs Limited [Unit-3]  
92 Sipcot Industrial Complex  
Hosur-635 126  
Tamil-Nadu, India  
Email: [jainethesh@microlabs.in](mailto:jainethesh@microlabs.in)

For any information about this medicine, contact the supplier.

**This leaflet was last revised in July 2022.**

*Detailed information on this medicine is available on the World Health Organization (WHO) website:*  
<https://extranet.who.int/pqweb/medicines>